Shanghai, Aug 31, 2026 — Shanghai’s Medical Procurement Center opened the online application channel for the fourth batch and second-batch renewal of the National Traditional Chinese Medicine Patent Medicines and Simple Preparations Purchasing Alliance centralized procurement, requiring selected manufacturers to complete platform registration by Sept 15, 2026.
Policy Snapshot
| Attribute | Detail |
|---|---|
| Issuer | Shanghai Medical Centralized Bidding and Procurement Affairs Management Center |
| Document | Notice on Launching Application and Networking for Fourth and Second Batch Renewal of National TCM Patent Medicines Purchasing Alliance |
| Batches | ZCYLM-2026-1 (Fourth Batch); ZCYLM-2026-2 (Second Batch Renewal) |
| Application window | Aug 31, 2026 – Sept 15, 2026 |
| Platform | Shanghai Medical Procurement Association portal (www.smpaa.cn) |
| Module | Business Operations → My Drug Library |
| Listing type | Non-national centralized procurement related drugs |
| Sub-type | National alliance centralized procurement, renewal drugs (selected channel) |
Key Provisions
- Mandatory filing — All drugs on Shanghai’s supply list for the two batches must be registered; previously listed selected drugs are exempt from re-application.
- Digital workflow — Enterprises log into the procurement subsystem via the SMPAA portal, navigate to the drug library module, and select the designated listing categories to submit product information.
- Supply lists — Two annexes detail the selected varieties: the fourth batch (ZCYLM-2026-1) and the second-batch renewal (ZCYLM-2026-2).
Market Impact Analysis
The 16-day application window creates a tight compliance timeline for TCM manufacturers seeking to maintain Shanghai market access under the national alliance procurement framework. By routing the fourth batch and renewal products through a dedicated “selected channel” within the non-national centralized procurement category, regulators are preserving the distinction between national volume-based procurement and alliance-level TCM procurement while streamlining the local listing process.
For pharmaceutical companies, failure to register by the Sept 15 deadline risks exclusion from Shanghai’s public hospital and community health center formularies, a significant volume channel in one of China’s wealthiest healthcare markets. The exemption for already-listed products reduces administrative duplication but requires manufacturers to verify their current platform status against the new supply lists.
Forward-Looking Statement
Industry analysts expect Shanghai’s listing template to be replicated across other alliance member provinces in September, as the national TCM procurement alliance synchronizes local platform onboarding ahead of the fourth-quarter procurement cycle. The second-batch renewal mechanism suggests the alliance is transitioning toward a rolling contract model for mature TCM products, potentially reducing annual re-tendering friction. Companies with selected TCM formulations should prioritize the Shanghai digital registration workflow, as delays in the initial listing phase could cascade into missed procurement windows across the alliance network. Final supply list confirmations are anticipated by late September 2026.-China Health Reform Pulse
Policy Source: https://www.smpaa.cn/xxgk/gggs/2026/08/31/24240.shtml